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Abstract
Background: Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. The
clinical spectrum of IgAN varies from minor urinary abnormalities to rapidly progressive renal failure. Evaluation of
the disease by repeated renal biopsy is not practical due to its invasive procedure. Urinary sediment miRNAs
promise to serve as non-invasive biomarkers to assess kidney injury of IgAN.
Methods: Fifty two biopsy-proven IgAN patients and twenty five healthy controls were enrolled in the study. Urinary
sediment miRNAs were extracted. Expressions of miR-34a, miR-205, miR-21, miR-146a and miR-155 were quantified by
real-time quantitative polymerase chain reaction (RT-QPCR). The receiver operating characteristic (ROC) curve was used
to investigate the value of the miRNAs for predicting diagnosis of IgAN and evaluating histopathological injury. The
patients were treated according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines and followed
up. The roles of miRNAs in reflecting therapeutic efficacy and disease progression were analyzed.
Results: 1. The IgAN group had significantly lower urinary miR-34a, miR-205, and miR-155, but higher miR-21 levels
than controls. The ROC revealed that urinary miR-34a≤ 0.047, miR-205≤ 0.209, miR-21≥ 0.461 and miR-155≤ 0.002
could distinguish patients with IgAN from healthy ones. In addition, miR-205≤ 0.125 and miR-21≥ 0.891 can
distinguish IgAN patients with severe tubular atrophy/interstitial fibrosis from those with mild tubular atrophy/
interstitial fibrosis. 2. After a mean 15.19 months follow-up, the reduction of proteinuria (g/24 h/year) was positively
correlated with baseline urinary miR-21 and inversely correlated with miR-205. The levels of baseline eGFR and miR-205 in
the complete remission group were significantly higher than non-complete remission group (p< 0.001; p= 0.018), while
proteinuria, miR-21 and miR-146a were lower than non-complete remission group (p= 0.002; p= 0.021; p= 0.009). But
multivariate analysis revealed that only baseline eGFR correlated with the remission of IgAN (p= 0.001, OR = 1.042).
Conclusions: The levels of some urinary sediment miRNAs, especially baseline miR-21 and miR-205, may be used as
potential prognostic markers for evaluating the tubulointerstitial damage of IgAN. Furthermore, baseline levels of urinary
miRNAs may be predictors of therapeutic efficacy and disease progression.
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Background
Immunoglobulin A nephropathy (IgAN) is the most com-
mon form of primary glomerulonephritis throughout the
world, characterized by deposition of polymeric IgA in the
mesangium, mesangial proliferation, and activation of
proinflammatory and profibrotic mediators [1–3]. About
15–40% of patients with IgAN will progress to end-stage
renal disease (ESRD) in 5–25 years [4]. Repeated renal bi-
opsy is not practical to evaluate the disease severity and
progression because it is an invasive technique. Thus, the
investigation of non-invasive novel biomarkers based on
the pathogenesis of IgAN has been a research focus.
MicroRNAs (miRNAs) are noncoding, single-stranded
RNA molecules, regulating gene expression through
post-transcriptional degradation of messenger RNA or
translational inhibition of protein synthesis [5]. Dysregu-
lation of miRNAs has been associated with many human
diseases.
Recently, it has been reported that miR-34a is involved
in cell proliferation. Down-regulation of miR-34a has been
shown in different types of cancer, such as pancreatic can-
cer [6] and colon cancer [7]. Moreover, miR-34a declines
the proliferation activity of mesangial cells in the anti-
Thy1 mesangial proliferative glomerulonephritis rat
models [8]. IgA nephropathy is characterized by mesangial
cell proliferation and increased matrix. Thus, we hypothe-
sized that miR-34 might participate in the pathological
process of mesangial cell proliferation of IgAN.
Previous data reported that miR-205 inhibited cell pro-
liferation and induced apoptosis in melanoma cells,
through downregulated E2F1, a critical factor involved
in cell cycle progression from G1 to S phase [9]. In
addition, epithelial-mesenchymal transition (EMT) plays
an important role in tumor invasion and metastasis.
Studies have indicated that miR-205 is a negative regula-
tor of EMT, by repressing ZEB1 and ZEB2, major tran-
scription repressors of E-cadherin, a key marker of
epithelial cells [10, 11]. We speculated that miR-205
might be involved in the process of cell proliferation
and/or EMT of IgAN.
Recent studies reported a major role of miR-21 in
mediating the pathogenic activation of lung and cardiac
fibroblasts and, ultimately, fibrosis [12, 13]. An abun-
dance of miR-21 is also observed in both tubulointersti-
tial and glomerular area where fibrosis happens in
mouse models of obstructive and diabetic nephropathy
[14, 15]. Transforming growth factor beta (TGF-β) is a
well-known mediator of renal fibrosis [16], and miR-21
is positively induced by TGF-β signaling [17]. Given the
established role of miR-21 in tissue fibrosis, we decided
to assess whether urinary miR-21 was a reliable noninva-
sive marker of kidney fibrosis in IgAN.
Previous studies have proven that miR-146a and miR-
155 are two important regulators in both immune and
inflammatory response [18, 19]. For instance, expres-
sions of miR-146a and miR-155 were higher in synovial
fibroblasts of rheumatoid arthritis (RA) patients as com-
pared with controls [20, 21]. MiR-146a expression was
elevated in the tissues associated with chronic inflamma-
tory diseases such as psoriasis [22]. An up-regulation of
miR-155 was also observed after stimulation in vitro
with TNF-α, IL-1β and toll-like receptor (TLR) ligand.
Therefore, we hypothesized that miR-146a and miR-155
might be involved in the pathological process of immune
and inflammatory response of IgAN.
In this study, we evaluated the levels of miR-34a, miR-
205, miR-21, miR-146a, and miR-155 in the urine sedi-
ments of IgAN patients, aiming to explore the roles of




A total of 52 patients with biopsy-proven IgAN, and 25
healthy normal control (NC) participants matched by
age and sex were enrolled in the study. The inclusion
criteria were: patients signed informed consent; age ≥ 18.
We excluded the following: patients with secondary IgA
nephropathy; patients who had received corticosteroids
or immunosuppressants before the beginning of this
study; patients who had undergone kidney transplant-
ation and who were undergoing dialysis; patients with
systemic diseases such as diabetes; the number of
glomerulus in renal biopsy tissues ≤8; patients who were
pregnant, planning a pregnancy, or those who were
breastfeeding. After the renal biopsy, the patients were
treated with corticosteroids or angiotensin-converting
enzyme inhibitors (ACEIs)/angiotensin receptor blockers
(ARBs), according to the Kidney Disease: Improving
Global Outcomes (KDIGO) guidelines and followed up
for at least 12 months. Complete remission (CR) was de-
fined as the absence of proteinuria (proteinuria < 0.3 g/
24 h) along with the lack of worsening of renal function.
Partial remission (PR) was defined as a ≥50% reduction
in proteinuria from baseline. No response (NR) was de-
fined as a <50% reduction in proteinuria [23, 24]. Glom-
erular filtration rate (GFR) was estimated by the chronic
kidney disease epidemiology (CKD-EPI) equation [25].
The study was approved by the Clinical Research Ethical
Committee of Chinese PLA General Hospital.
Sample preparation
Morning urine specimens of 150–250 ml from patients
before renal biopsy and from controls were collected
and processed immediately or stored at 4 °C overnight.
Then, the urine samples were centrifuged at 3000 g for
30 min and at 13,000 g for 5 min at 4 °C. The superna-
tants were discarded, and the urinary sediments were
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then stored at −80 °C until use. The kidney tissues were
obtained by method of percutaneous renal biopsy. Sec-
tions were stained routinely by hematoxylin and eosin
(H & E), periodic acid–Schiff stain (PAS) and periodic
acid silver methenamine (PASM).
Measurement of miRNA levels
Total RNA was extracted from urinary sediments using
Trizol® (Invitrogen) according to the manufacturer’s in-
structions. Briefly, the tube containing the urinary
sediments, Trizol, and chloroform was centrifuged. Sub-
sequently, the remaining aqueous phase supernatant was
removed into another tube, and equal volume of isopro-
panol was added, followed by mixing and incubation in
ice. Then, samples were centrifuged and the supernatant
discarded. RNA pellets were washed two times with 75%
ethanol in diethylpyrocarbonate (DEPC) and then dried
at room temperature, and DEPC was added. The RNA
was used immediately or stored at −80 °C in 75%
alcohol.
Micute miRNA First-Strand cDNA Synthesis Kit
(TIANGEN, CHINA) was used for reverse transcription.
For Poly(A), total RNA was mixed with 0.4 μ1 E.coli
Poly(A) Polymerase (5U/μL), 2 μ1 10 × Poly(A) Polymer-
ase Buffer, 4 μ1 5 × rATP solution and made up to 20 μl
with RNase-Free ddH2O. The reaction was carried out
at 37 °C for 60 min. For miRNA, 4 μl Poly (A) was
mixed with 4 μl 10 × RT Primer (10 μM), 4 μl 10 × RT
Buffer, 2 μl Super Pure dNTP (2.5 mM each), 2 μl RNase
(40 U/μl), 1 μl Quant RTase and made up to 40 μl with
23 μl RNase-Free ddH2O. Reverse transcription was
performed at 37 °C for 60 min. The resulting cDNA was
stored in −80 °C until use.
Urinary levels of miRNAs were quantified by RT-
QPCR using the ABI Prism® 7900 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA). For
RT-QPCR, 10 μl 2 × miRcute miRNA Premix, 0.4 μl For-
ward Primer, 0.4 μl Reverse Primer (10 μM), 2 μl
miRNA cDNA and 7.2 μl ddH2O were mixed to make a
20 μl reaction volume. Each sample was run in triplicate.
Real-time quantitative polymerase chain reaction (RT-
QPCR) was performed at 94 °C for 2 min, followed by
40 cycles at 94 °C for 20 s and 60 °C for 34 s. Results
were analyzed with Sequence Detection Software,
Version 2.0 (Applied Biosystems). RNA U6 was used as
an endogenous control for normalizing the miRNA ex-
pression in urine sediments. The relative quantitation of
miRNAs in the samples was evaluated as fold change
calculated by the comparative Ct method (2-△△Ct).
Evaluation of renal histopathological damage
The severity of histopathological damage was scored by
two experienced pathologists who were blinded to the
patients’ data, using the Oxford classification scoring
system. The mesangial hypercellularity score was re-
corded as M1 for instances in which more than half the
glomeruli have more than three cells in a mesangial area.
Otherwise, the score was reported as M0. Endocapillary
hypercellularity and segmental glomerulosclerosis were
scored as present or absent (i.e. E1 or E0, and S1 or S0).
Tubular atrophy/interstitial fibrosis was classified
according to the percentage of cortical area involved by
the tubular atrophy or interstitial fibrosis: <25% as T0,
26–50% as T1, and >50% as T2.
Statistical analysis
Normally distributed data were expressed as mean ± SD
and were compared using the t-test or one-way ANOVA.
Nonparametric variables were expressed as medians,
with corresponding 25th and 75th (interquartile range),
and compared using the Mann–Whitney or Kruskal–
Wallis tests. Categorical data were expressed as percent-
ages and compared using the chi-squared test. Pearson
or Spearman’s correlation was used to analyze correla-
tions. We constructed receiver operating characteristic
(ROC) curves and calculated the area under the ROC
curve (AUC) to investigate the value of the miRNAs for
predicting IgAN and evaluating histological injury. Stat-
istical significance was considered as P < 0.05.
Results
Clinical and pathological characteristics of patients with
IgAN
Fifty-two IgAN patients were enrolled in our study. Of
them, 31 were males and 21 were females. 20 were
treated with renin angiotensin system (RAS) blockade
alone and 32 were treated with steroids and/or immuno-
suppressants. The age at renal biopsy was 33.45 ±
10.36 years old. The baseline characteristics of IgA ne-
phropathy patients and healthy controls are listed in
Table 1.
Levels of urinary miRNAs in IgAN patients and controls
As shown in Fig. 1, the urinary expressions of miR-34a,
miR-205, and miR-155 were significantly lower, while miR-
21 were higher in the IgA group than in the NC group
(0.025 (0.004–0.099) vs 0.060 (0.022–0.426), p < 0.001; 0.036
(0.002–0.459) vs 0.281 (0.025–1.573), p < 0.001; 0.001
(0.000–0.168) vs 0.013 (0.000–0.165), p= 0.005; 0.587
(0.159–1.936) vs 0.365 (0.050–1.005), p= 0.019). The levels
of miR-146a were of no difference between two groups
(0.006 (0.000–0.051) vs 0.005 (0.000–0.035), p= 0.827).
Correlations between urinary miRNAs and clinical
parameters
The levels of urinary miR-205 were positively correlated
with eGFR (r = 0.316, p = 0.025), and negatively corre-
lated with 24 h urinary protein excretion (U-Prot),
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cystatin, and uric acid (r = −0.415, p = 0.003; r = −0.500,
p = 0.001; r = −0.389, p = 0.006). Expressions of miR-21
were positively correlated with U-Prot, cystatin (r =
0.362, p = 0.008; r = 0.462, p = 0.002), and negatively
correlated with eGFR and urine osmosis (r = −0.481, p <
0.001; r = −0.385, p = 0.017).
Correlations between urinary miRNAs and
histopathological parameters
For mesangial proliferation, the levels of urinary miR-
205 were significantly lower in patients with M1 than
those in patients with M0 (0.049 ± 0.070 vs 0.112 ±
0.129, p = 0.032). For segmental glomerulosclerosis and
endocapillary hypercellularity, the levels of urinary miR-
34a, miR-205, miR-21, miR-146a, and miR-155 showed
no significant difference between patients with S1 and
S0, E1 and E0. The levels of miR-205 decreased as the
Fig. 1 Urinary expression of miRNAs between patients with IgA nephropathy (IgAN) and normal controls (NC)
Table 1 The baseline characteristics of IgA nephropathy
patients and healthy controls
IgAN Healthy Control
No. of cases 52 25
Sex (M/F) 31/21 13/12
Age (year) 33.45 ± 10.36 33.72 ± 7.77
Scr (μmol/L) 104.78 ± 46.30 60.04 ± 9.37
U-Prot (g/24 h) 1.99 (0.64–2.91) 0.029 (0.007–0.064)
eGFR (ml/mim/1.73 m2) 84.67 ± 32.45 131.25 ± 11.68
Oxford score
M0/M1 (n) 31/21 –
E0/E1 (n) 47/5 –
S0/S1 (n) 28/24 –
T0/T1/T2 (n) 29/12/11 –
Note: Scr, serum creatinine; U-Prot, 24 h urinary protein excretion; eGFR,
estimated glomerular filtration rate
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severity of tubular atrophy or interstitial fibrosis in-
creased; they were significantly lower in patients with a
score of T1 and T2 than those with T0 (0.044 ± 0.040 vs
0.129 ± 0.134, p = 0.011; 0.015 ± 0.011 vs 0.129 ± 0.134, p
< 0.001) (Fig. 2a). However, the levels of miR-21 were
upregulated in patients with severe tubular atrophy or
interstitial fibrosis. They were higher in patients scored
as T2 than in those scored as T0 (1.144 ± 0.656 vs 0.516
± 0.283, p = 0.036) (Fig. 2b). Besides, crescents existed in
27 (51.9%) biopsy specimens of 52 IgAN patients. The
levels of miR-21 were positively correlated with the ra-
tios of crescents (r = 0.294, p = 0.035). The association
between the urinary miRNAs and the clinical and patho-
logical characteristics were summarized in a synthetic
table (Additional file 1).
Prediction values of urinary miRNAs in IgAN patients
ROC analysis revealed that urinary miR-34a, miR-205,
miR-21, and miR-155 levels discriminated patients with
IgAN from NC, with AUC values of 0.86, 0.85, 0.66 and
0.71, respectively. The cutoff values were miR-34a ≤
0.047 (Fig. 3a), miR-205 ≤ 0.209 (Fig. 3b), miR-21 ≥ 0.461
(Fig. 3c), and miR-155 ≤ 0.002 (Fig. 3d). More import-
antly, miR-205 and miR-21 can distinguish patients with
T1 and T2 tubular atrophy/interstitial fibrosis from
patients with T0, with AUC values of 0.74 and 0.74. The
cutoff values were miR-205 ≤ 0.125 (Fig. 3e) and miR-
21 ≥ 0.891 (Fig. 3f ).
Correlation between urinary miRNAs and clinical
remission
Of the 52 IgAN patients, one provided only routine urine
protein tests, such as 2+, but no exact 24 h urine protein-
uria. The mean time of follow-up was 15.19 months (10–
19.67 months). There were no correlations between the rate
of eGFR loss (ml/min/1.73 m2/year) and levels of baseline
miRNAs. The reduction of U-prot (g/24 h/year) were corre-
lated positively with baseline miR-21 (r = 0.288, p= 0.041),
and correlated negatively with miR-205 (r = −0.414, p=
0.003). We divided the 51 patients into CR and non-CR
groups after the follow-up. The results are summarized in
Table 2. The levels of baseline miR-205 in the CR group
were significantly higher than non-CR group (p= 0.018),
while miR-21 and miR-146a were lower than non-CR group
(p= 0.021; p= 0.009). The patients who achieved a complete
remission of proteinuria also had severer tubular atrophy/
interstitial fibrosis (p= 0.005). We further investigated the
factors associated with CR using logistic analysis. Only
higher baseline eGFR contributed to the CR in IgAN pa-
tients (p= 0.001, OR= 1.042). Considering the effect of dif-
ferent therapies, we investigated the correlation of baseline
parameters and remission of proteinuria under different
therapies. In patients treated with steroids and/or immuno-
suppressants, the levels of baseline miR-146a in the CR
group were significantly lower than non-CR group (0.004
(0.001–0.006) vs 0.010 (0.004–0.023), p= 0.014). While in
patients treated with RAS blockers alone, the levels of base-
line miR-205 in the CR group were significantly higher than
non-CR group (0.139 (0.076–0.295) vs 0.012 (0.009–0.061),
p= 0.021).
Discussion
The clinical course of IgAN is extremely variable,
ranging from minor urinary abnormalities to rapidly
progressive renal failure. Thus, the investigation of non-
invasive and more reliable biomarkers to sequentially as-
sess kidney injury and disease progression is crucial.
Recent studies found that miRNAs can be secreted by
cells into body fluids and these circulating miRNAs are
highly stable [26–30]. Produced by the kidney and pass-
ing through almost all kidney cell types, urine may
Fig. 2 Correlations between urinary miRNAs and severity of tubular atrophy/interstitial fibrosis. a. Levels of urinary miR-205 in patients with different
scores of tubular atrophy/interstitial fibrosis. b. Levels of urinary miR-21 in patients with different scores of tubular atrophy/interstitial fibrosis. #, signifi-
cant difference between patients with T1 and T0. *, significant difference between patients with T2 and T0
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contain miRNAs that can serve as biomarkers for kidney
diseases [31, 32].
MiR-34a induces G1 arrest and inhibits cell prolifera-
tion by regulation of several cell cycle genes, including
cyclin D1 (CCND1), cyclin E2 (CCNE2), CDK4, CDK6
[33, 34]. MiR-34a is also reported to regulate cell prolif-
eration by reducing the levels of anti-apoptotic protein
BCL-2 [35] and transcription factor E2F3 [36]. Our
studies showed that urinary expressions of miR-34a were
significantly lower in IgAN than in NC group, but there
were no significant correlations between miR-34a levels,
clinical indicators, and pathological damages in IgAN.
Studies with larger sample and basic experiments are
needed to confirm the roles of miR-34 in the pathogen-
esis of IgAN.
Renal fibrosis is the final outcome of many chronic
kidney diseases [37]. Activated myofibroblasts and
epithelial-mesenchymal transition (EMT) play important
roles in the progression of renal fibrosis [38]. It is
reported that tubulointerstitial fibrosis is an important
factor affecting the development and prognosis of IgAN
[39, 40]. One of the hallmarks of EMT is the loss of E-
cadherin, which responsible for cell-cell adhesion and
maintenance of cytoskeletal organization. Transcription
factors ZEB1 and ZEB2 can inhibit the transcription of
E-cadherin [11]. Studies have shown that miR-205 might
mediate the repression of ZEB1 and ZEB2, resulting in
E-cadherin up-regulation and EMT repression [10].
There is increasing evidence that miR-21, which pro-
motes fibrosis, plays a major role in the progression of
Fig. 3 Receiver operating characteristic (ROC) curve analysis of the prediction values of miRNAs in IgAN patients. a-d ROC curve of discriminating
IgAN from healthy controls. e-f ROC curve of discriminating IgAN patients with tubular atrophy/interstitial fibrosis T1 and T2 from patients with
T0. 95% CI, 95% confidence interval; AUC, area under the curve
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renal disease [41, 42]. Glowacki F et al. [43] found miR-
21 to be highly upregulated in the kidneys of mice with
unilateral ureteral obstruction (UUO) and in the kidneys
of patients with severe kidney fibrosis. Zhong X et al.
[44] also found that miR-21 participates in renal fibrosis
through positively regulating the expression of extracel-
lular matrix (ECM) and a-SMA in tubular epithelial cells
(TECs) and fibrotic kidneys. Our study showed that the
IgAN group had significantly lower urinary miR-205 but
higher miR-21 levels than controls. The ROC revealed
that miR-205 ≤ 0.125 and miR-21 ≥ 0.891 can distinguish
patients with severe tubular atrophy/interstitial fibrosis
from patients with mild tubular atrophy/interstitial fi-
brosis. These data indicate that the urinary miR-205 and
miR-21 parallel with the severity of tubulointerstitial
damage in IgAN.
Our results showed no correlations between miR-
146a, miR-155 and clinical parameters and histological
features. There is a negative feedback loop in immune
cells. Stimulation of TNF receptor associated factor 6
(TRAF6) could enhance NF-κB activity, which upregu-
lates miR-146a expression. The increased miR-146a
level, in turn, suppresses TRAF6 and NF-kB activity,
which properly terminates the immune response [45].
The urinary samples of IgAN that were collected in dif-
ferent periods of the negative feedback may lead to con-
troversial results.
Proteinuria is a strong prognostic factor for IgAN pro-
gression [46, 47]. Reich et al. reported that persistent
proteinuria is the strongest predictor of poor renal out-
come in IgAN and that sustained reduction of
proteinuria to <1 g/24 h is associated with a good prog-
nosis [48]. In this study, we regarded the remission of
proteinuria as main clinical outcome. The results
showed that the reduction of U-Prot (g/24 h/month)
was correlated with baseline urinary miR-21 and in-
versely correlated with miR-205. The subjects who
achieved a complete remission had higher baseline urin-
ary miR-205, lower miR-21 and miR-146a than those did
not achieve a complete remission. Altogether, these data
suggest miR-205 and miR-21 might be novel, reliable
urinary biomarkers of kidney fibrosis and predictors of
progression of IgAN. Targeting miR-205 and miR-21
might provide significant therapeutic effects in IgAN.
Our study has limitations. First, we detected the
urinary miRNA expressions in urine sediments, which
consist of different cell types, such as red blood cells,
lymphocytes, and renal tubular cells. We did not deter-
mine their cellular source. In addition, healthy people
were used as controls in this study. The results were
helpful to distinguish patients with IgAN from healthy
people, but not exclude an association between other
chronic kidney diseases and miRNAs. Including another
cohort of patients with kidney disease other than IgAN
will be more conclusive. This was a single-center study
with a limited number of patients. Studies involving a
larger sample and followed up for a longer time are
needed in further.
Conclusions
In conclusion, in the first part of the study, we showed a
significant reduction of miR-34a, miR-205, and miR-155
Table 2 Comparison of baseline clinical parameters and urinary miRNAs levels between CR and non-CR groups
CR Non-CR P value
No. of patients, n (%) 27 24
Age (years) 32.52 ± 10.66 33.83 ± 9.81 0.650
Baseline GFR (ml min−11.73 m−2) 100.91 ± 23.12 66.90 ± 32.94 <0.001*
Baseline proteinuria (g/d) 0.77 (0.62–1.58) 2.55 (1.03–4.47) 0.002*
Baseline ALB (g/L) 41.08 ± 4.19 36.13 ± 8.88 0.018*
Baseline NAG 32.74 ± 22.57 44.30 ± 35.99 0.218
Baseline osmosis 713.40 ± 218.80 592.22 ± 187.28 0.080
miR-34a 0.031 ± 0.023 0.026 ± 0.018 0.440
miR-205 0.113 ± 0.123 0.045 ± 0.058 0.018*
miR-21 0.537 ± 0.301 0.857 ± 0.584 0.021*
miR-146a 0.003 (0.002–0.010) 0.009 (0.004–0.023) 0.009*
miR-155 0.002 (0.000–0.028) 0.002 (0.001–0.030) 0.298
M0/M1 20/7 12/12 0.076
E0/E1 26/1 24/0 1.000
S0/S1 16/11 13/11 0.714
T0/T1/T2 20/6/1 10/5/9 0.005*
*, Statistical significance with P < 0.05
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but an increase of miR-21 in the urine of patients with
IgAN. Then, we demonstrated a significant correlation
between the urinary miR-205 and miR-21 with histologic
lesions, especially tubulointerstitial damages. Finally, we
assessed the prognosis effect of urinary miRNAs on re-
mission of proteinuria. The levels of miR-205, miR-21
and miR-146a, measured at the time of renal biopsy,
predicted the outcome in IgAN patients. These findings
supported the notion that urinary miRNAs can serve to
reflect tubulointerstitial damage and predict the progres-
sion of IgAN.
Additional file
Additional file 1: Association between the urinary miRNAs and the
clinical and pathological characteristics. (DOCX 102 kb)
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